Gene therapy strategies for colon cancer

Molecular Medicine

Volumn 6, Issue 2, 2000, Pages 82-87

  Chung Faye, Guy A ^b   Kerr, David J ^a,b   Young, Lawrence S ^a,b   Searle, Peter F ^b  

^a Department of Clinical Oncology ^*

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; COLORECTAL CANCER; GENE TECHNOLOGY; GENE THERAPY; HUMAN; IMMUNOMODULATION; REVIEW;

ANIMALS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; GENE THERAPY; GENES, P53; GENES, RAS; HUMANS; IMMUNOTHERAPY, ACTIVE; PRODRUGS; SUBSTRATE SPECIFICITY; VACCINES, SYNTHETIC;

EID: 0033969415     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1357-4310(99)01598-1     Document Type: Review

References (42)

1. Midgley, R. and Kerr, D.J. (1999) Seminar in colorectal cancer. Lancet 353, 391-399
2. Ozturk, M. et al. (1992) p53 as a potential target in cancer therapy. Bone Marrow Transplant. 9, 164-170
3. Levine, A.J. (1997) p53, the cellular gatekeeper for growth and division. Cell 88, 323-331
4. Baker, S.J. et al. (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249, 912-915
5. Harris, M.P. et al. (1996) Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther. 3, 121-130
6. Bouvet, M. et al (1998) Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res. 58, 2288-2292
7. Sakakura, C. et al. (1995) Inhibition of colon cancer cell proliferation by antisense oligonucleotides targeting the messenger RNA of the Ki-ras gene. Anti-Cancer Drugs 6, 553-561
8. Roth, J.A. (1996) Modification of mutant K-ras gene expression in non-small cell lung cancer (NSCLC). Hum. Gene Ther. 7, 875-889
9. Pardoll, D.M. (1993) Cancer vaccines. Immunol. Today 14, 310-316
10. Todryk, S. and Lemoine, N. (1998) Can immunotherapy by gene transfer tip the balance against colorectal cancer. Gut 43, 445-449
11. Harding, F.A. et al. (1992) CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356, 607-609
12. Fearon, E.R. et al. (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397-403
13. Caruso, M. et al. (1996) Adenovirus-mediated interleukin 12 gene therapy for metastatic colon carcinoma. Proc. Natl. Acad. Sci. U. S. A. 93, 11302-11306
14. Gunji, Y. et al. (1996) Antitumor effect induced by the expression of granulocyte macrophage-colony stimulating factor gene in murine colon carcinoma cells. Cancer Lett. 101, 257-261
15. Sobol, R.E. et al. (1995) Injection of colon carcinoma patients with autologous irradiated tumor cells and fibroblasts genetically modified to secrete interleukin-2 (IL-2): a Phase I study. Hum. Gene Ther. 6, 195-204
16. Chong, H. et al. (1998) Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony-stimulating factor induces a local antitumour response and may generate systemic protective immunity. Gene Ther. 5, 223-232
17. Kantor, J. et al. (1992) Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J. Natl. Cancer Inst. 84, 1084-1091
18. Tsang, K.Y. et al. (1995) Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J.Natl Cancer Inst. 87, 982-990
19. Conry, R. et al. (1995) Breaking tolerance to CEA with a rV virus vaccine in man (abstr.). Proc. Am. Assoc. Cancer Res. 36, 492
20. Plautz, G.E. et al. (1994) Direct gene transfer for the understanding and treatment of human disease. Ann. New York Acad. Sci. 716, 144-153
21. Rubin, J. et al. (1997) Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. Gene Ther. 4, 419-425
22. Vogelzang, N. et al. (1996) Clinical experience in Phase I and Phase II testing of direct intratumoural administration with Allovectin-7: a gene based immunotherapeutic agent. ASCO Proceedings 17, 235
23. Yang, L. et al. (1998) Intercellular communication mediates the bystander effect during herpes simplex thymidine kinase/ganciclovir-based gene therapy of human gastrointestinal tumor cells. Hum. Gene Ther. 9, 719-728
24. Link, C.J., Jr et al. (1997) Gene therapy for colon cancer with the herpes simplex thymidine kinase gene. J. Surg. Oncol. 64, 289-294
25. Mullen, C.A. et al. (1992) Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. U. S. A. 89, 33-37
26. Austin, E.A. and Huber, B.E. (1993) A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol Pharmacol. 43, 380-387
27. Huber, B.E. et al. (1994) Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. U.S.A. 91, 8302-8306
28. Green, N.K. et al (1997) Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther. 4, 229-238
29. Crystal, R.G. et al (1997) Phase I study of direct administration of a replication deficient adenovirus vector containing the E coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum. Gene Ther. 8, 985-1001
30. Morsy, M. and Caskey, C. (1999) Expanded capacity adenoviral vectors - the helper-dependent vectors. Mol. Med. Today 5, 18-24
31. Dmitriev, I. et al. (1998) An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72, 9706-9713
32. Reynolds, P. et al. (1999) Chimeric viral vectors - the best of both worlds? Mol. Med. Today 5, 25-31
33. Chen, S.H. et al. (1996) Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res. 56, 3758-3762
34. Lowe, S.W. et al. (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847-849
35. Lowe, S.W. et al. (1993) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967
36. Ogawa, N. et al. (1997) Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent. Int. J. Cancer 73, 367-370
37. Richards, C. A. et al. (1995) Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum. Gene Ther. 6, 881-893
38. Lan, K.H. et al. (1996) Tumor-specific gene expression in carcinoembryonic antigenproducing gastric cancer cells using adenovirus vectors. Gastroenterology 111, 1241-1251
39. Lan, K.H. et al. (1997) In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Res. 57, 4279-4284
40. Bischoff, J.R. et al. (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376
41. Habib, N.A. et al. (1999) Elb-deleted adenovirus gene therapy for liver tumours (abstr.). Cancer Gene Ther. 6, 389
42. Roth, J.A. and Cristiano, R.J. (1997) Gene therapy for cancer what have we done and where are we going? J. Natl. Cancer Inst. 89, 21-39